Five years after the University of Pennsylvania began recruiting a small group of 14 patients with hard-to-treat chronic lymphocytic leukemia, researchers are still tracking three of them who are still alive with no signs of their cancer returning after being treated with a first-generation CAR-T therapy.
Last week saw two developments by players large and small in a universal flu vaccine race that's heating up. Now, Israel-based BiondVax is following up with some news of its own: It's partnering with the National Institute of Allergy and Infectious Diseases to test its candidate in the U.S.
Novo Nordisk has hit a roadblock in its drive to expand the label for Victoza to cover use in Type 1 diabetics. The snag arose when Victoza failed to deliver hypoglycaemic benefit experienced by Type 2 diabetics in people with the other form of the disease in a Phase III trial.
Vital Therapies has joined the growing list of biotechs crushed by a single catalyst after it reported late Friday that their cell-based therapy for liver damage had failed a late-stage study.
An in-development pain treatment from Vernalis missed its main goal in a proof-concept study, leading the U.K. drugmaker to back away from a drug it once believed could bring in more than $500 million a year.
Things are heating up in the race for a respiratory syncytial virus (RSV) vaccine.Novavax reported Phase II results for its investigational vaccine just a week ago, and now, Danish biotech Bavarian Nordic is starting a Phase I trial of its candidate.
Kite CEO Arie Belldegrun has a simple message for investors this morning: Relax.
Roche is spotlighting another success for its PD-L1 checkpoint drug atezolizumab, with company execs applauding a positive finish in a big mid-stage study in non-small cell lung cancer. The news follows a string of steady pipeline advancements for a drug that has emerged as the pharma giant's biggest single late-stage blockbuster contender.
Adynxx says that their second shot at statistically significant results in a midstage study for their lead pain drug proved the charm. The San Francisco-based biotech didn't post any data, but CEO Rick Orr said that the drug hit the primary endpoint without raising any red flags on the safety side.
Merck's Ebola vaccine, developed in tandem with NewLink, has protected 100% of patients from Ebola infection, according to interim results published in The Lancet on Friday.